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Indications for Ascending
Aortic Replacement
Size Alone Is Not Enough*
Donald D. Glower, MD
Durham, North Carolina
Literature over the last 2 decades has progressively lowered
the threshold for ascending aortic replacement at the time of
aortic valve replacement. Current American College of
Cardiology (ACC)/American Heart Association (AHA)
guidelines recommend replacing the ascending aorta at the
time of aortic valve replacement if the ascending aorta is
more than 5.0 cm in any patient or if the ascending aorta is
more than 4.5 cm in bicuspid patients (1). Yet, despite the
simplicity of these guidelines, many factors play a role in
determining the indications for ascending aortic replace-
ment to prevent ascending aortic complications. In addition
to increased absolute aortic diameter, observed to expected
aortic diameter ratio (2), genetics (3), rate of aortic expan-
sion (2,3), body size (1,3,4), smoking (5), and hypertension
(5) have been demonstrated to be influential.
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The bicuspid aortic valve is known to be a phenotype
associated with many genotypes, some of which are consid-
ered to be “connective tissue” disorders (3,6). For a given
ascending aortic diameter, the presence of a bicuspid aortic
valve has been associated with increased risk of aortic
complications relative to a tricuspid aortic valve (3). In other
words, the presence of a tricuspid aortic valve would be
expected to have less risk of aortic complications than a
bicuspid valve of the same diameter.
The work by Gaudino et al. (7), in this issue of the
Journal, is one of the few studies to examine the natural
history of the ascending aorta in patients with tricuspid
aortic valves. Only a few small reports have provided
outcome data for patients with enlarged ascending aortas in
the absence of either Marfan syndrome or bicuspid disease
(8,9). Michel et al. (9) noted that in patients undergoing
aortic valve replacement alone for degenerative aortic regur-
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these patients subsequently required ascending aortic re-
placement.
Most studies have focused on the size threshold for com-
plications for patients with Marfan syndrome, bicuspid pa-
tients (6,10), or mixed populations that include bicuspid valves
(4,5,11). In fact, studies cited to justify the replacement of
aortas larger than 5.0 cm all examined mixed populations that
included bicuspid valves (1,3,5,12,13). Other studies of mixed
bicuspid and tricuspid populations still found 6.0 cm to be the
point at which risk of aortic complications increases dramati-
cally in unoperated patients (3,13).
Gaudino et al. (7) provide convincing data that at least
some patients with a tricuspid aortic valve and an ascending
aortic diameter of 5.0 to 5.9 cm can have the ascending
aorta left alone during aortic valve replacement, contrary to
ACC/AHA guidelines (1). In 93 consecutive patients un-
dergoing isolated replacement of a tricuspid aortic valve
with a 5.0 to 5.9 cm ascending aorta left intact, no patient
suffered an aortic complication or significant aortic enlarge-
ment over a mean follow-up of 14 years. The researchers
concluded that the increase in operative risk related to
ascending aorta surgery does not appear justified in patients
with moderate post-stenotic dilation (6.0 cm) of the
ascending aorta in the absence of connective tissue disease.
The data of Gaudino et al. (7) do have limitations. The fact
that only 93 patients came to surgery with aortas of 5.0 to 5.9
cm, whereas 381 patients came to surgery with aortas5.9 cm
suggests a referral bias in which patients with aortas of less than
6.0 cm were less likely to be referred for surgery. We do not
know how many patients with aortas of 5.0 to 5.9 cm ruptured
their aortas without referral to surgery in this referral network.
Furthermore, we do not know if patients in the study by
Gaudino et al. (7) might have been larger, if there might have
been more men, or if the patients were less likely to have aortic
regurgitation than other series, making aortic sizes respectively
larger. Nonetheless, it is remarkable and important that none
of the 93 patients who did have surgery for aortas 5.0 to 5.9
mm ever developed an aortic complication, and none ever
needed aortic replacement.
One could also question the assumption of Gaudino et al.
(7) that addition of ascending aortic grafting adds signifi-
cant risk to an aortic valve replacement. The risk of aortic
valve replacement alone may be 1% to 5%, whereas the risk
of aortic valve replacement with ascending aortic grafting
has similarly been reported at 2.5% to 5% (6). Thus, failing
to graft the ascending aorta at the time of aortic valve
replacement only makes sense if the risk of leaving the
ascending aorta alone is less than approximately 3% (the
difference between aortic valve replacement without vs. with
aortic grafting). In the current study, the risk of leaving the
ascending aorta alone was 0 of 93 (0%), which would have
a 95% confidence interval of 0.0% to 3.5%. In short, this
study, as large as it were, is marginally powered to demon-
strate at a 95% confidence level that the risk of leaving the
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93 (0%) mortality by leaving the ascending aorta alone does,
however, suggest that further study is warranted.
Clearly these data will need to be confirmed by other
investigators. Yet the article is important in adding new data
from a reasonably sized series with excellent follow-up. Should
the results of Gaudino et al. (7) be confirmed, then ACC/
AHA guidelines should be made more specific regarding
different patient groups (e.g., Marfan, bicuspid, tricuspid), as in
Table 1 (2). Other disease etiologies (such as degenerative
ortic regurgitation or chronic dissection) might require more
r less aggressive approaches than the 3 etiologies in Table 1 (2,9).
Thus, evidence supports the contention of Gaudino et al. (7)
hat size alone is not enough to indicate replacement of the
scending aorta in many patients with aortas of less than 6.0
m in diameter. Other factors such as disease etiology, genetics,
ate of enlargement, body size, hypertension, quality of the
orta itself, and concurrent indication for cardiac surgery all
ust be considered. Guidelines are just guidelines. Guidelines
eed to be applied to individual patients by knowledgeable
hysicians.
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Etiology-Specific Guidelines for Ascending AorticRep acement: Aortic Diameter Threshold forAscending Aortic Replacement*
Table 1
Etiology-Specific Guid li es for Ascending Aortic
Replacement: Aortic Diameter Threshold for
Ascending Aortic Replacement*
Marfan Syndrome Bicuspid Tricuspid Non-Marfan
With AVR, cm 4.0 4.5 (5.0) 6.0
Without AVR, cm 4.5 5.0 (5.5) 6.0
*Subject to further study and adjustment for body size, rate of enlargement, and other factors.
Current guidelines/practice are in parentheses.
AVR  aortic valve replacement.Carolina 27705. E-mail: glowe001@mc.duke.edu.REFERENCES
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